Takeda Pharmaceutical said on June 26 that it has filed for approval of an updated version of the COVID-19 vaccine Nuvaxovid in Japan. The updated product is tailored to the currently circulating XFG Omicron subvariant of SARS-CoV-2. The application seeks…
To read the full story
Related Article
BUSINESS
- Sanofi Files Venglustat for Gaucher Disease in Japan
June 29, 2026
- Toho Shareholders Approve Trigger for 3D Defense Measures
June 29, 2026
- Nippon Shinyaku Bags Option on Elixirgen’s DMD Candidate
June 29, 2026
- UK Accepts Taletrectinib Filing for ROS1+ NSCLC: Eisai
June 29, 2026
- Takeda Files XFG-Adapted COVID Vaccine in Japan
June 29, 2026
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…





